<DOC>
	<DOCNO>NCT00036205</DOCNO>
	<brief_summary>The primary objective ass long term safety tolerability sumanirole measure safety lab , ECG monitoring , vital sign , adverse event report subject Parkinson 's Disease participate previous sumanirole study .</brief_summary>
	<brief_title>Open Label Sumanirole Study Safety , Tolerability , Therapeutic Response In Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Idiopathic Parkinson 's disease Modified Hoehn Yahr Scale Stages 14 Age 30 year Previous participation prior sumanirole study Use dopamine agonist medication medication define timeframe Unstable dose CNS active therapy ( eg , hypnotic , antidepressant , anxiolytic ) within last 30 day Atypical Parkinson 's syndrome due drug , metabolic disorder , encephalitis , degenerative disease Dementia History active epilepsy within past year Significant liver disease define laboratory criterion Significant renal disease define laboratory criterion Certain cardiac condition Electroconvulsive therapy previous 90 day Subjects participate drug study receive investigational drug within previous 30 day Positive pregnancy test Screen Unwillingness use adequate contraceptive method Lactating woman History stereotaxic brain surgery Malignant melanoma history treat melanoma</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>